SCHEMBL5451709

SCHEMBL5451709

NC(=O)c1c(NC(=O)C2CC2)sc2c1CCOC2NCc1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.41
IKBKB O14920 1/20 0.40
ALDH1A1 P00352 5/20 0.37
HPGD P15428 3/20 0.37
TSHR P16473 2/20 0.37
MAPK10 P53779 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MDM2 Q00987 1/20 0.37
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 1/20 0.36
CYP3A4 P08684 1/20 0.36
MGAM O43451 1/20 0.36
AMY1A P0DUB6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459168 0.91 FLT3 (0.40) FLT3IKBKBALDH1A1HPGDTSHR
SCHEMBL5458319 0.81 FLT3 (0.46) FLT3IKBKBALDH1A1HPGDTSHR
SCHEMBL5455200 0.76 FLT3 (0.46) FLT3IKBKBALDH1A1HPGDTSHR
SCHEMBL5457860 0.75 FLT3 (0.44) FLT3IKBKBALDH1A1HPGDTSHR
SCHEMBL5450745 0.74 FLT3 (0.46) FLT3ALDH1A1HPGDTSHRMAPK10
SCHEMBL5454125 0.74 FLT3 (0.43) FLT3ALDH1A1HPGDTSHRMAPK10
SCHEMBL5457867 0.73 KMT2A (0.46) FLT3ALDH1A1HPGDTSHRMAPK10
SCHEMBL5451643 0.72 FLT3 (0.55) FLT3ALDH1A1HPGDTSHRMAPK10
SCHEMBL5453191 0.71 KMT2A (0.45) FLT3ALDH1A1HPGDTSHRMAPK10
SCHEMBL5458311 0.70 FLT3 (0.52) FLT3ALDH1A1HPGDTSHRMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885IKBKB 1034/4885ALDH1A1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.